William Blair analyst Myles Minter reiterated a Buy rating on Verve Therapeutics (VERV – Research Report) today. The company’s shares opened ...
Verve Therapeutics (VERV) announced the clearance of its Investigational New Drug application by the U.S. Food and Drug Administration for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback